Article Details
Retrieved on: 2022-09-08 16:37:36
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The US FDA has granted Breakthrough Therapy Designation to Pfizer's GBS6 or PF-06760805 to prevent invasive Group B Streptococcus (GBS) disease.
Article found on: www.pharmaceutical-business-review.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here